Auris Medical Holding Ltd. (NASDAQ: EARS) plunged almost -26.77% at $4.21 in post-market hours, returning some of what it enormously attained yesterday after the news of upbeat results from the AM-301 in vitro test. AM-301 is a drug-free nasal spray designed by Altamira Medica, a group subsidiary, to protect against respiratory infections and allergens.
AM-301 has been tested for its ability to resist or reduce contamination with SARS-CoV-2 in nasal epithelial cells that are part of the nasal mucosa and are the first barrier to continually inhaled contaminants such as pathogens and allergens. The procedure was conducted on reconstituted human nasal epithelia over four days and is mostly used to study human respiratory viruses’ symptoms.
Sars-CoV-2 replicated effectively in saline-treated control cultures, resulting in a rapid increase in viral titer formation (as measured by the Median Tissue Culture Infectious Dose, TCID50). In comparison, regular care with AM-301 demonstrated good defense against viral infection, starting right before inoculation.
Average virus titers were 90.0 percent smaller than those found in controls 48 hours post-infection (p<0.05). The average virus titers were 99.2 and 99.4 percent smaller, respectively, 72 hours and 96 hours after infection (p<0.001). The decrease in viral titer was 92.4 percent relative to saline-treated controls (p<0.001), even though the unbound virus was not eliminated every day by apical washing, causing the virus to accumulate in the culture for four days.
